Krystal Biotech slides as investors appear to reset ahead of earnings

Krystal Biotech (KRYS) is down 8.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The catalyst is not fully clear, and no obvious new negative company announcement surfaced with today’s drop. This could be because traders are taking profits and reducing risk ahead of Krystal Biotech’s August 3, 2026 earnings report after a strong run in the shares, while also reassessing pipeline disclosures that did not amount to full clinical readouts.

Details:

Krystal Biotech said on July 23 that it will report second-quarter 2026 financial results on August 3 before the U.S. market opens, with a management call scheduled for 8:30 a.m. EDT.

In its most recent quarterly update, the company posted first-quarter 2026 net revenue of $116.4 million from VYJUVEK and net income of $55.9 million, setting a high bar for the next report.

S&P Dow Jones Indices said last week that Krystal Biotech would join the S&P MidCap 400, a change that can sometimes lift shares beforehand and leave room for a pullback once the event passes.

A July 21 SEC filing disclosed a single-patient KB801 observation showing closure of a persistent corneal epithelial defect, but the company also cautioned that the data came from a discontinued study and should not be used to draw broader conclusions on safety or efficacy.

Sources:

Krystal Biotech Investor Relations, SEC, Nasdaq, TipRanks

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$KRYS Insider Trading Activity

$KRYS insiders have traded $KRYS stock on the open market 76 times in the past 6 months. Of those trades, 0 have been purchases and 76 have been sales.

Here’s a breakdown of recent trading of $KRYS stock by insiders over the last 6 months:

DANIEL JANNEY has made 0 purchases and 22 sales selling 71,964 shares for an estimated $19,402,207.
SUMA KRISHNAN (President, R&D) has made 0 purchases and 21 sales selling 50,000 shares for an estimated $14,283,095.
KRISH S KRISHNAN (President and CEO) has made 0 purchases and 21 sales selling 50,000 shares for an estimated $14,282,148.
DINO A ROSSI has made 0 purchases and 2 sales selling 18,950 shares for an estimated $4,953,694.
KATHRYN ROMANO (Chief Accounting Officer) has made 0 purchases and 8 sales selling 13,250 shares for an estimated $3,602,405.
JOHN CHARLES THOMAS (EVP, General Counsel) has made 0 purchases and 2 sales selling 1,642 shares for an estimated $541,173.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$KRYS Hedge Fund Activity

We have seen 206 institutional investors add shares of $KRYS stock to their portfolio, and 130 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

VESTOR CAPITAL, LLC added 700,714 shares (+350357.0%) to their portfolio in Q2 2026, for an estimated $260,434,372
CITADEL ADVISORS LLC removed 383,779 shares (-99.3%) from their portfolio in Q1 2026, for an estimated $99,137,791
SOLEUS CAPITAL MANAGEMENT, L.P. added 212,028 shares (+22.5%) to their portfolio in Q1 2026, for an estimated $54,771,072
MARSHALL WACE, LLP removed 115,411 shares (-62.8%) from their portfolio in Q1 2026, for an estimated $29,812,969
FIRST TRUST ADVISORS LP added 105,245 shares (+42.9%) to their portfolio in Q1 2026, for an estimated $27,186,888
RAYMOND JAMES FINANCIAL INC added 79,526 shares (+103.9%) to their portfolio in Q1 2026, for an estimated $20,543,156
GOLDMAN SACHS GROUP INC removed 78,576 shares (-26.8%) from their portfolio in Q1 2026, for an estimated $20,297,752

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$KRYS Price Targets

Multiple analysts have issued price targets for $KRYS recently. We have seen 8 analysts offer price targets for $KRYS in the last 6 months, with a median target of $344.0.

Here are some recent targets:

Ritu Baral from TD Cowen set a target price of $403.0 on 06/18/2026
Joseph Pantginis from HC Wainwright & Co. set a target price of $361.0 on 06/16/2026
Gavin Clark-Gartner from Evercore ISI Group set a target price of $300.0 on 05/05/2026
Yigal Nochomovitz from Citigroup set a target price of $378.0 on 05/05/2026
Debjit Chattopadhyay from Guggenheim set a target price of $284.0 on 02/25/2026
Geulah Livshits from Chardan Capital set a target price of $323.0 on 02/18/2026
Roger Song from Jefferies set a target price of $371.0 on 02/17/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.